Skip to main content
. 2020 Nov 25;23(2):92. doi: 10.3892/mmr.2020.11731

Table II.

Results of TrMab-6 immunostaining in 61 breast cancers.

TrMab-6

Pathological diagnosis No. of cases 3+ 2+ 1+ No. of positive cases (%)
Invasive ductal carcinoma 54 26 16 8 4 50/54 (92.6)
Invasive lobular carcinoma 4 1 2 1 0 4/4 (100)
Adenocarcinoma 2 2 0 0 0 2/2 (100)
Medullary carcinoma 1 1 0 0 0 1/1 (100)
Total 61 30/61 (49.2%) 18/61 (29.5%) 9/61 (14.8%) 4/61 (6.6%) 57/61 (93.4%)